stage oral tongu cancer otc gener favor prognosi earli otc case poor prognosi otc known propens subclin nodal metastasi moreov devis strategi take account possibl recurr distant metastasi current studi previous untreat patient stage otc underw surgic treatment elig review author investig associ clinico-patholog factor diseas outcom examin postop cours patient poor prognosi most common caus death distant metastasi late cervic lymph node metastasi lcm significantli independ prognost variabl lcm treat salvag surgeri central issu control patient distant metastis free diseas loco-region site
delin role chromosom aberr non-medullari thyroid tumor perform cytogenet analys establish thyroid cancer cell line primari tumor us spectral karyotyp sky g-band compar genom hybrid cgh five primari thyroid tumor reveal abnorm karyotyp follicular thyroid carcinoma observ two transloc loss chromosom 10p papillari thyroid carcinoma ptc balanc transloc reveal case metastat ptc carri sever clonal transloc involv ten differ chromosom numer aberr observ two five follicular adenoma analyz both lead gain chromosom materi furthermor cytogenet character three establish thyroid cancer cell line cgth w-1 aro dro sky combin g-band reveal structur numer karyotyp abnorm three cell line breakpoint region partli overlap primari tumor copi number chang detect cgh correl well karyotyp find demonstr high-level amplif chromosom result provid evid chromosom region involv non-medullari thyroid tumorigenesi character observ transloc lead identif novel fusion oncogen thyroid cancer
purpos review nurs assess manag regard care patient primari hyperparathyroid degre hpth evolv parallel mark chang diagnosi surgic approach diseas earlier diagnosi vast advanc surgic approach shift paradigm nurs intervent outpati set recent find earli detect degre hpth becom preval preced three decad clinic profil shift minim symptomat asymptomat patient excess serum pth level along hypercalcemia recent consensu confer propos diagnost guidelin relev decis make process regard advis surgic intervent medic manag surgic intervent definit treatment degre hpth success outcom associ outpati minim invas parathyroidectomi shift pattern recommend surgeri group asymptomat patient summari endocrin nurs integr success team manag patient diagnos degre hpth nurs perspect paradigm shift inpati focu center around progress clinic sign symptom diseas comprehens patient care model assess educ pre peri postop monitor patient benefit demonstr posit outcom associ parathyroid surgeri outpati set
thyroid cancer uncommon tumor account roughli malign differenti papillari follicular thyroid carcinoma usual asymptomat frequent appear solitari thyroid nodul few show cervic lymphadenopathi metastasi lung bone liver fine needl aspir fna recommend initi diagnost test depend size lesion associ risk factor most patient treat total total thyroidectomi postop radioiodin ablat perform tumor potenti recurr recurr rate cancer-specif mortal decreas suppress thyroid stimul hormon tsh long-term surveil follow-up physic examin everi month year annual patient remain cancer free whole bodi iodin scan done everi month follow-up on neg scan withdraw thyroid hormon rhodium complex -tsh thyroglobulin measur antithyroglobulin antibodi ultrasound neck suggest month annual diseas free
object s100a4 calcium-bind protein relat metastat potenti carcinoma order elucid contribut progress thyroid carcinoma investig s100a4 express variou thyroid neoplasm method immunohistochem examin s100a4 express 195 case thyroid neoplasm result s100a4 absent normal follicular cell follicular adenoma s100a4 posit 115 case papillari carcinoma examin includ microcarcinoma howev signific relationship establish s100a4 express clinicopatholog featur papillari carcinoma follicular carcinoma wide invas type express s100a4 frequent minim invas type 0.0028 anaplast carcinoma s100a4 express 61.9 case incid significantli lower &lt 0.0001 papillari carcinoma conclus find suggest s100a4 plai constitut role papillari carcinoma s100a4 us marker earli detect carcinoma
long-term treatment metastat medullari thyroid carcinoma mtc somatostatin sst analog evalu patient persist relaps diseas vivo posit sst receptor sstr tumor surgic intervent patient on initi later time persistenli relaps elev serum calcitonin 252-69482 pg/ml carcinoembryon antigen cea 8-1130 ng/ml concentr show posit uptak 111in-pentetreotid scan daili dose 0.4-1.0 octreotid subcutan monthli dose 20-30 long-act octreotid lar intramuscularli 3-21 month administ system chemotherapi extern radiotherapi ert given patient simultan benefici effect pre-exist diarrhea observ patient subject partial remmiss spr 36.4 patient show stabl diseas worsen pre-exist diarrhea observ cea concentr decreas patient patient show decreas biolog object respons tumour growth demonstr patient survivor group treat ch+ert plu octerotid show higher 92.5 lower mortal 23.1 longer mean time death 130 month longer mean total surviv mt time 145 month comparison group patient 66.7 33.3 mortal 88.5 month mean time death 101 month mt-time long-term octreotid octreotid-lar treatment offer subject biolog partial remiss on third on fourth mtc patient respect doe improv natur cours tumor remain answer drug combin antineoplast therapi synergist effect relat treatment respons patient surviv mortal
knowledg molecular event govern human thyroid tumorigenesi grown consider past ten year kei genet alter oncogen pathwai identifi molecular genet aberr thyroid carcinoma bear noteworthi resembl acut myelogen leukemia thyroid carcinoma myeloid leukemia both possess transcript factor gene rearrang-ppargamma-relat transloc thyroid carcinoma raralpha-relat cbf-relat transloc amongst other myeloid leukemia ppargamma raralpha close relat member ofth same nuclear receptor subfamili pml-raralpha pax8-ppargamma fusion protein both function domin neg inhibitor wild-type parent protein thyroid carcinoma myeloid leukemia both harbor nra mutat 15-25 both cancer receptor tyrosin kinas mutat--ret mutat thyroid carcinoma flt3 mutat myeloid leukemia nra tyrosin receptor kinas mutat observ same thyroid carcinoma leukemia patient suggest multipl initi pathwai exist both thyroid carcinoma myeloid leukemia possess p53 mutat rel low frequenc 10-15 patient tend older aggress therapi resist diseas parallel unlik occur chanc alon argu common mechan underli divers epitheli hematolog cancer comparison thyroid carcinoma myeloid leukemia highlight area thyroid cancer investig worthi focu exampl few collabor mutat defin thyroid carcinoma plai clear role myeloid leukemia exemplifi raralpha rearrang flt3 mutat togeth dictat promyleocyt leukemia phenotyp function interact collabor mutat possibl multipl level tempt specul thyroid carcinoma develop through uniqu combin co-activ ret ra ret ppargamma signal system fact el1-ret ptc3 fusion protein contain el1 nuclear receptor co-activ domain appear physic associ inhibit wild-type ppargamma papillari carcinoma similar fusion protein thyroid carcinoma myeloid leukemia suggest direct search fusion gene non-thyroid carcinoma warrant fact novel fusion gene identifi recent aggress midlin secretori breast renal cell carcinoma epitheli natur latter well-document interestingli cancer tend present frequent adolesc young adulthood manner similar thyroid myeloid malign fusion gene analys cancer present earlier life enhanc fusion gene recognit carcinoma type definit biolog character precursor cell give rise thyroid carcinoma will import myeloid leukemia thought aris stem/progenitor cell acquir disturb self-renew differenti capac retain characterist myeloid lineag presenc compar stem/progenitor cell thyroid defin distinct thyroid cancer lineag pattern differenti exist candid stem/progenitor cell p63-immunoreact solid cell nest appar import area develop molecular-base therapi thyroid carcinoma patient resist standard radio-iodin treatment treatment cancer limit pathwai defin thyroid cancer mutat prime target pharmacolog intervent molecular inhibitor tyrosin kinas inhibitor nuclear receptor ligand proven dramat effect myeloid leukemia patient variou molecular inhibitor investig thyroid cancer model develop predict thyroid cancer model will continu provid biolog insight human carcinoma biologi improv patholog diagnosi treatment thyroid cancer patient sit distant horizon
us molecular assai analyz clinic tissu diagnosi manag thyroid cancer similar tumor will like allow accur character aggress individu tumor allow earli diagnosi recurr applic method thyroid nodul nodal metastas encumb difficulti aris amplif transcript non-thyroid cell tissu assai like us clinic near-futur data aris cdna arrai identifi novel marker malign tumor aggress make grow area interest us molecular assai diagnos distant metastas problemat due issu ectop express full length splice variant gene thought thyroid-specif assai quantit complex problem ow variabl level express housekeep gene varieti phlebotomi rt-pcr method report addit research area clearli requir befor recommend given regard clinic applic test
decad sever line evid accumul support exist fptc suscept gene preliminari clinic characterist fptc identifi linkag studi identifi chromosom locat put fptc suscept gene logic clinic approach fptc emerg
inactiv p53 tumor suppressor gene on most frequent genet alter observ human esophag carcinoma patient esophag carcinoma on signific patholog featur tumor presenc multipl lesion esophagu howev molecular mechan involv occurr multipl lesion remain elus character p53 alter multipl esophag carcinoma studi role carcinogenesi perform p53 immunohistochem p53 mutat analys us laser captur microdissect surgic resect human esophag carcinoma patient patient multipl esophag carcinoma intramur metastasi lesion esophagu intraepitheli carcinoma lesion contigu main lesion patient multipl esophag carcinoma examin sampl main lesion repres concomit lesion molecular analys sampl fresh-frozen normal tissu tumor tissu main lesion whole tumor perform same method p53 protein accumul observ 72.7 lesion case p53 mutat found normal esophag tissu case multipl esophag carcinoma point mutat detect whole tumor 11.1 case microdissect tumor sampl main lesion 33.3 case microdissect tumor sampl concomit lesion 33.3 case microdissect tumor sampl 54.5 12/22 concord rate result immunostain molecular analysi case whole tumor p53 mutat observ case reveal p53 mutat microdissect tumor sampl main lesion case multipl esophag carcinoma show p53 mutat microdissect tumor sampl discord p53 mutat statu main concomit lesion contrast both intramur metastasi lesion intraepitheli carcinoma contigu main lesion show p53 mutat pattern ident main lesion conclus analysi microdissect dna laser captur microdissect us character heterogen p53 gene mutat multipl carcinoma lesion accur analyz whole esophag tumor dna find differ p53 gene mutat among multipl esophag carcinoma lesion suggest evid multicentr field carcinogenesi human esophagu
multicent case-control studi conduct northern southern taiwan clarifi independ combin effect alcohol intak tobacco smoke betel quid chew risk esophag cancer total 513 patient newli diagnos histopatholog confirm squamou cell carcinoma esophagu 818 gender ag studi hospit-match control includ found signific dose-respons relationship durat intens consumpt substanc develop neoplasm site amount alcohol consum stronger effect risk esophag cancer number year consum howev number year on smoke stronger effect risk amount cigarett consum strongest risk factor esophag cancer alcohol intak highest risk 13.9 consum 900 g/dai-year combin exposur substanc brought risk 8.8-19.7 fold substanc 41.2-fold multipl interact effect alcohol drinker smoke cancer risk detect wherea addit interact effect found among drinker chew combin effect substanc account 83.7 attribut fraction contract esophag cancer popul conclus result suggest intens length time alcohol tobacco us plai differ role etiolog esophag cancer alcohol separ interact tobacco betel quid differ synergist wai determin develop site cancer
esophag cancer incid mortal rate linxian china among highest world examin risk factor esophag squamou cell carcinoma escc gastric cardia cancer gcc gastric noncardia cancer gncc popul-base prospect studi 584 adult particip linxian gener popul trial studi particip complet baselin questionnair includ question demograph characterist person famili histori diseas lifestyl factor year follow-up total 410 incid upper gastrointestin cancer identifi includ 958 escc 089 gcc 363 gncc cox proport hazard model us estim risk increas ag posit famili histori esophag cancer includ escc gcc significantli associ risk cancer site addit risk factor escc includ born linxian increas height cigarett smoke pipe smoke gcc male gender consumpt moldi bread pipe smoke gncc male gender cigarett smoke protect factor escc includ formal educ water pipe home increas consumpt meat egg fresh fruit increas bmi gcc formal educ water pipe home increas consumpt egg fresh fruit alcohol consumpt gncc increas weight bmi gener socioeconom statu se common denomin factor improv se promis approach reduc tremend burden upper gastrointestin cancer linxian
autoantibodi detect patient esophag cancer appli serolog analysi recombin cdna express librari serex case esophag squamou cell carcinoma order identifi tumor antigen cdna librari deriv esophag cancer cell line bacteri express screen interact antibodi five allogen sera patient esophag squamou cell carcinoma examin specif immunoreact antigen sera patient esophag squamou cell carcinoma patient gastric cancer patient colon cancer patient breast cancer healthi volunt screen identifi independ cdna clone potenti encod esophag cancer tumor antigen identifi cdna clone surf1 hook2 cenp-f zic2 hcla-iso ki-1/57 enigma hca25a spk two est clone name loc146223 agencourt_7565913 sero-posit rate antibodi surf1 loc146223 hook2 agencourt_7565913 significantli higher esophag cancer patient healthi control least on antibodi detect sera esophag cancer patient diseas-specif humor immun respons surf1 loc146223 hook2 agencourt_7565913 observ most patient esophag squamou cell carcinoma antibodi serex antigen repres pool candid serum tumor marker esophag squamou cell carcinoma
ongo phase studi design assess outcom surviv failur pattern therapi local esophag cancer convent dose radiat 50.4 concurr continu infus 5-fluorouracil 5-fu weekli carboplatin/paclitaxel patient complet respons partial respons receiv dose escal radiat 59.4 same chemotherapi report detail result first patient treat juli 2000 june 2003 prospect enrol patient t1-4 n0-1 m0-1a esophag carcinoma receiv paclitaxel mg/m intraven hour carboplatin auc intraven minut dai 5-fluorouracil 225 mg/m2 deliv continu infus dai through radiat therapi given 1.8 dai/week 5.5 week 50.4 fraction week patient underw repeat stage comput tomographi scan endoscop ultrasound biopsi patient posit biopsi partial respons comput tomographi endoscop ultrasound receiv boost same concurr chemotherapi patient follow everi month comput tomographi/endoscop ultrasound first year everi month thereaft median follow-up month eleven patient 61.1 attain complet respons/partial respons six 33.3 receiv boost overal surviv year median month patient pretreat weight loss overal surviv median month patient pretreat weight loss median surviv month surviv year local/region control no-boost patient [78 boost patient [40 progress-free surviv year median month distant metastasi-free surviv year median month seventi-nine percent patient requir least on dose reduct chemotherapi becaus toxic radiat delai rang dai median dai grade 2/3 acut esophag experienc patient respect patient develop esophag strictur requir dilat combin continu-infus 5-fu weekli carboplatin/paclitaxel select radiat dose escal yield promis result surgeri adjuv chemotherapi toxic therapi manag signific
background transform growth factor beta tgf-beta superfamili regul cell growth variou cell previou studi shown alter express tgf-beta receptor smad2 smad4 mediat tgf-beta superfamili signal contribut tumor progress esophag squamou cell carcinoma scc express smad6 smad7 neg regul examin investig effect tgf-b superfamili signal materi method immunohistochem stain anti-smad6 anti-smad7 polyclon antibodi perform surgic specimen obtain 115 patient esophag scc result express smad6 smad7 invers correl depth invas earli stage 0.0003 0.0173 respect moreov signific correl express smad6 smad7 poor surviv rate 0.0078 0.0207 respect conclus smad6 smad7 express affect progress earli lesion esophag scc indic poor prognosi
background &amp materi method recent prove pgp9.5 oncogen candid squamou cell carcinoma examin pgp9.5-relat oncogen pathwai test global pattern gene express cancer cell pgp9.5 gene introduct us oligonucleotid microarrai approach result plasminogen activ inhibitor-1 pai-1 identifi overexpress gene pgp9.5-express esophag squamou cancer cell line confirm data obtain perform northern analysi us pgp9.5 pai-1 cdna probe found pai-1 mrna induc pgp9.5 express nuec1 cell examin endogen pgp9.5 pai-1 express esophag cancer cell line on cell line nuec2 pgp9.5 express exhibit pai-1 express suggest possibl pgp9.5 induc pai-1 directli indirectli conclus result suggest pai-1 novel downstream mediat pgp9.5 esophag squamou cell carcinoma
background best treatment option patient local advanc esophag carcinoma yet determin especi becaus benefit esophagectomi neoadjuv chemoradiotherapi still controversi report result retrospect cohort comparison definit chemoradiotherapi surgeri crt versu neoadjuv chemoradiotherapi follow plan surgeri crt patient advanc esophag squamou cell carcinoma scc materi method januari 1991 decemb 2002 patient enrol studi fifti patient consid inoper tumor due distant organ metastasi distant lymph node metastasi sever organ dysfunct reject surgeri patient receiv crt remain patient treat crt clinic respons primari tumor evalu result crt patient on- 2-year surviv rate 33.8 20.2 respect median surviv time mst 13.5 month crt patient respons rate 76.5 patholog complet respons pcr rate 29.4 on- 2-year surviv rate 61.6 35.9 respect mst 24.4 month surviv rate crt patient lower crt patient 0.1288 patient distant organ metastas remov crt group on- 2-year surviv rate remain patient 36.5 24.1 respect mst 14.7 month surviv rate crt patient distant organ metastas similar crt patient patholog partial respons ppr group 0.6279 conclus retrospect cohort comparison crt versu crt demonstr surviv benefit addit surgeri ppr group advanc esophag carcinoma patient poor respons neoadjuv chemoradiotherapi suggest addit chemoradiotherapi instead plan esophagectomi show similar surviv rate definit crt larg seri random control studi will requir confirm benefit surgeri chemoradiotherapi
object determin genet polymorph cyp1a1 gstm1 gstp1 gstt1 associ increas risk develop esophag squamou cell carcinoma escc gastric cardia cancer gcc high-risk asian popul method conduct case-cohort analysi year prospect follow-up analyt cohort contain 642 individu particip dysplasia trial gener popul gpt nutrit intervent trial conduct linxian china includ 131 case escc case gcc genotyp analysi perform dna extract red blood cell us puregen kit gentra system inc minneapoli real-time pcr analysi amplif taq-man rel risk confid interv estim us case cohort estim cox proport hazard model p-valu nest model genotyp variabl came score test result rel risk develop escc gcc cancer calcul entir analyt cohort gstm1 p1*b a313g cyp1a1*2a t3801c *2c a2455g genotyp signific associ identifi howev becaus differ cancer risk 9.3 case per 1000 person year gpt 5.3 case analyt cohort stratifi trial particip heterozyg homozyg variant-allel cyp1a1*2a reduc risk develop gcc adjust 0.47 0.23-1.00 0.037 conclus studi found associ cyp1a1*2a variant allel reduc risk gcc peopl high risk develop diseas find consist previou studi suggest substrat cytochrom p-450 1a1 metabol pathwai polycycl aromat hydrocarbon etiolog signific high-risk region
background diagnosi thyroid carcinoma cours lobectomi domin nodul occasion render basi frozen section onc diagnosi carcinoma made question complet thyroidectomi aris patient method period year patient diagnos well-differenti thyroid cancer wdtc oper total thyroidectomi admit depart patient clinic radiolog evid residu diseas time admiss submit total thyroidectomi result men women averag ag 38.6+/-1.3 year rang year postop morbid complet thyroidectomi consist transient hypoparathyroid patient 7.1 perman hypoparathyroid patient 3.5 recurr laryng nerv palsi haematoma patient seroma patient complet thyroidectomi result detect patient 32.1 have residu diseas clinic manifest conclus surgeon advoc total near-total thyroidectomi differenti thyroid carcinoma surgeon hesit complet thyroidectomi lobectomi thyroid nodul clinic evid suggest bilater diseas fear ad morbid patient howev demonstr studi complet thyroidectomi shown fairli safe procedur carri low incid complic facilit manag follow-up radioact iodin decis perform complet thyroidectomi wdtc base patient's risk categori concern risk complic second procedur
background worldwid esophag carcinoma on most aggress cancer rel common countri character poor prognosi rapid clinic progress purpos studi aim evalu role cd34 marker vascular endotheli cell mmp-9 matrix metalloproteinas type p53 esophag carcinoma materi method forti-four archiv tissu specimen case esophag carcinoma six case normal mucosa immunohistochem stain monoclon antibodi cd34 mmp-9 p53 addit flow cytometr dna analysi carri patient control result result show dna content diploid normal esophag mucosa wherea aneuploidi detect twenti case 52.6 thirti-eight case show posit express cd34 antigen express mmp-9 identifi mainli cytoplasm most cancer cell case hand 73.7 posit p53 express statist signific cd34 mmp-9 p53 express tumor stage microvessel densiti patient highli posit stain mmp-9 higher neg weak stain mmp-9 0.002 conclus data suggest express cd34 mmp-9 associ tumor progress possibl seem valuabl marker offer addit inform aggress activ esophag carcinoma lesion
